Exelixis, Inc. EXEL

EXEL Company Overview

Exelixis, Inc. is a U.S.-based biotechnology company focused on the discovery, development, and commercialization of oncology therapeutics. The company operates primarily within the biopharmaceutical and precision oncology industries, with a strategic emphasis on targeted cancer therapies and combination treatment regimens. Exelixis generates the majority of its revenue from sales of cabozantinib-based products, particularly CABOMETYX, which is approved for multiple cancer indications including renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. The company also earns collaboration and licensing revenue through partnerships with larger pharmaceutical companies.

Exelixis was founded in 1994 and initially focused on genomics and drug discovery technologies before transitioning toward oncology therapeutics development. Its commercial transformation accelerated following the successful development and approval of cabozantinib, a tyrosine kinase inhibitor targeting MET, VEGFR, and related pathways implicated in tumor growth and metastasis. The company has positioned itself as a specialized oncology innovator with expertise in targeted therapies and clinical development in difficult-to-treat cancers.